cerebrovascular and cardiac events (MACCE) at 5 years, defined as a composite of death, myocardial infarction (MI), ischemic stroke, and repeat revascularization (RR). CONCLUSIONS Although risk of hard outcomes after PCI were still higher in the DM patients, the risk of revascularization was comparable between DM and non-DM patients in the era of DES. BACKGROUND It remains unclear whether there are differences in the safety and efficacy outcomes between everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for treatment of unprotected left main coronary artery stenosis.
RESULTS After multivariable adjustment, there were trend of increased 5-year risk of MACCE in the DM patients (Hazard ratio [HR] 1.128, 95% confidence interval [CI] 0.989-1.286 p¼0.072), mainly driven by increased risk of hard outcomes (HR 1.445, 95% CI 1.164-1.793, p¼0.001 for death; HR 1.289, 95% CI 1.067-1.558, p¼0.008 for composite of death, MI, and stroke). However, the risk of repeat revascularization was comparable between DM and non-DM patients (HR 1.021, 95% CI 0.861-1.211, p¼0.808), despite of unfavorable procedural characteristics, including lesser complete revascularization (36.5% vs. 39.0%, p¼0.082) and longer total stent length (62.9AE34.4mm vs. 60.0AE33.1mm, p¼0.001). The risk of target lesion revascularization (HR 1.146, 95% CI 0.913-1.440, p¼0.241) was also not significantly different between two groups.
Outcomes
Hazard ratio 95% confidence interval CONCLUSIONS Although risk of hard outcomes after PCI were still higher in the DM patients, the risk of revascularization was comparable between DM and non-DM patients in the era of DES. BACKGROUND It remains unclear whether there are differences in the safety and efficacy outcomes between everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for treatment of unprotected left main coronary artery stenosis.
METHODS From the IRIS MAIN Registry (total 4253 patients), we identified 1402 consecutive patients who received EES (982 patients) and ZES (420 patients). We compared major adverse cardiovascular events (MACE) which was defined as a composite measure consisting of death, nonfatal myocardial infarction, or target vessel revascularization (TVR).
RESULTS Mean age was 64.2AE10.4 years and 65.0AE10.6 years in the EES and ZES groups, respectively(p¼0.22). Male made up 76.4% and 79.8% (p¼0.17). There was no difference in the prevalence of diabetes between the two groups(p¼0.61). 2 year follow-up was completed in 40.9% of the EES group and 71.9% of the ZES group (p¼<0.001). At the 2-years of clinical follow-up, the EES and ZES groups did not differ significantly in the risk of MACE (10.9% for EES vs 6.4% for ZES; hazard ratio [HR], 1.36; 95% confidence interval [CI], 0.90-2.06, p¼0.14) with no difference in the individual component of MACE -death (HR, 1.72; 95% CI, 0.72-4.12, p¼0.22), MI (HR, 2.10; 95% CI, 0.47-9.34, p¼0.33), and TVR (HR, 1.21; 95% CI, 0.74-1.99, p¼0.44). The risk of cerebrovascular event (HR, 2.19 ; 95% CI, 0.49-9.78, p¼0.291) and definite stent thrombosis (HR, 0.004; 95% CI, 0.000 -564.85, p¼0.36) were also similar between the two groups. The risk of MACE between the two groups remained similar after adjusting for the difference in baseline characteristics, using the multivariate Cox's proportional hazard model. BACKGROUND Little is known about the clinical follow-up after sirolimus-eluting stent (SES) implantation and about the effect of SES implantation in in-stent restenosis (ISR) lesion more than five years. We aimed to compare clinical outcomes up to 10 years after SES implantation in de novo lesion and ISR lesion.
METHODS A series of 392 patients underwent the first SES implantation between November 2002 and December 2004, whose clinical outcomes were investigated. There were 253 patients for de novo lesion and 139 patients for ISR lesion. We evaluated the outcomes after SES implantation and clinical information was obtained either from a review of the hospital records or by telephone interviews with the patients, family members, or primary care physicians.
RESULTS Mean follow up period was 10.0 years. Cumulative incidence of major cardiac events (MACE) and target-lesion revascularization in ISR group were significantly higher than that in de novo group through 10 years (56.1% vs. 38.7%; p ¼ 0.01, and 41.3% vs. 20.6%; p ¼ 0.004, respectively) and the difference of the MACE and TLR rate in two groups increased in this period. Cumulative incidence of myocardial infarction (MI) and stent thrombosis (ST) between 2 groups were not significantly different (13.0% vs. 7.9%; p ¼ 0.1, and 5.0% vs. 2.4%; p ¼ 0.15, respectively).
CONCLUSIONS The incidence of MACE and TLR after the SES implantation in ISR lesion was significantly higher than that in de novo lesion and the difference of the TLR rate between in two lesions became more clear through 10 years, although the incidence of MI and ST had no significant difference in 2 groups.
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